Oligonucleotide therapeutic approaches for Huntington disease
Authors:
Open Access
- 1 February 2011
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 121 (2) , 500-507
Abstract
Huntington disease is an autosomal dominant neurodegenerative disorder caused by a toxic expansion in the CAG repeat region of the huntingtin gene. Oligonucleotide approaches based on RNAi and antisense oligonucleotides provide promising new therapeutic strategies for direct intervention through reduced production of the causative mutant protein. Allele-specific and simultaneous mutant and wild-type allele–lowering strategies are being pursued with local delivery to the brain, each with relative merits. Delivery remains a key challenge for translational success, especially with chronic therapy. The potential of disease-modifying oligonucleotide approaches for Huntington disease will be revealed as they progress into clinical trials.Keywords
This publication has 121 references indexed in Scilit:
- Allele-Selective Inhibition of Huntingtin Expression by Switching to an miRNA-like RNAi MechanismChemistry & Biology, 2010
- Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG RepeatBiochemistry, 2010
- RNAi therapeutics for CNS disordersBrain Research, 2010
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease MiceMolecular Therapy, 2009
- A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interferenceExperimental Neurology, 2009
- Five siRNAs Targeting Three SNPs May Provide Therapy for Three-Quarters of Huntington's Disease PatientsCurrent Biology, 2009
- Acetylation Targets Mutant Huntingtin to Autophagosomes for DegradationCell, 2009
- Sustained effects of nonallele‐specific Huntingtin silencingAnnals of Neurology, 2009
- Expression of shRNA From a Tissue-specific pol II Promoter Is an Effective and Safe RNAi TherapeuticMolecular Therapy, 2008
- Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic miceMolecular Therapy, 2005